16 September 2026 editorial review · Item
ELSA (EarLy Surveillance for Autoimmune diabetes): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: corrected/updated. Current item
lastReviewed: 2026-09-16. - Claim check: Official NHS ELSA page explicitly says currently paused. Changed available status/access score/summary/display; age 2–17 remains design eligibility. Removed fixed 10–15 year prediagnostic antibody lead-time; no reopening date assumed.
- Primary publication/regulatory sources checked or consulted: teplizumab-to-delay-the-onset-of-type-1-diabetes-recommended; ta1176; PMID 41576975; PMID 31180194.
- Programme/sponsor/conference source boundary: The ELSA Study — current participation status (registry); Type 1 Diabetes: Infant Testing — Hansard, House of Commons (regulatory); Type 1 Diabetes Screening (Children) Bill — UK Parliament (regulatory).